Herbert Raditya

Head Of Genomic Lab at Bumame

Herbert Raditya currently serves as the Head of Genomic Lab at Bumame since March 2024, after holding a similar position at PT. Diagnos Laboratorium Utama Tbk. from June 2021 to March 2024, where responsibilities included planning and managing laboratory operations and executing R&D initiatives involving Next Generation Sequencing technologies. Previously, Herbert held the position of Assistant Manager in the Corporate Strategy Department at Sequis Life, focusing on business planning and market analysis for the Indonesian Life Insurance industry. Early career experiences include internship roles at Baeckerei Brinker, Australian Indonesia Milk Industry (PT. Indomilk), and PT. Agarindo Bogatama, where contributions involved production planning, quality checks, and HACCP certification processes. Herbert Raditya holds a Master of Science in Biotechnology from Technische Universität Braunschweig, an MM/MBA in Finance from Universitas Prasetiya Mulya, and a Diplom Ingenieur & Bachelor of Science in Food Technology from Swiss German University.

Location

Jakarta, Indonesia

Links


Org chart

No direct reports

Teams

This person is not in any teams


Offices


Bumame

At Bumame, our purpose is to elevate healthcare in Indonesia by bridging the gap between cutting-edge technologies and accessible care, empowering lives through customer-centric innovations. We have partnered with best-in-class world leading strategic partners, introducing revolutionary medical services and adapting them to suit the unique needs of the Indonesian market. Bumame was founded early in 2020, in response to the Covid-19 pandemic. Building on our rapid rise as the #1 provider of COVID-19 services in Indonesia during the pandemic, we've pivoted to revolutionize other critical areas. Today, we're: • Indonesia's #1 provider of Non-Invasive Prenatal Test (NIPT) • Utilizing high-throughput sequencing platforms, providing next generation sequencing services  • Expanding our reach through a comprehensive portfolio of both routine pathology and specialized diagnostic solution • Pioneering advancements and affordable commercialization of world-class tests, with a focus on Mother & Child and Early Cancer Screening • Lead and manage analytical and clinical validation research services Our digital-first approach and best-in-class service set us apart. We're changing the standard of care delivery, poised to lead the Indonesian healthcare transformation. Join us: If you're passionate about delivering exceptional patient experiences and shaping the future of healthcare, let's connect!


Employees

201-500

Links